12:56 PM EDT, 03/21/2024 (MT Newswires) -- Immunic ( IMUX ) said Wednesday it has received a notice of allowance from the US Patent and Trademark Office covering a specific polymorph of vidofludimus calcium, its lead drug candidate.

The firm said its multi-layered intellectual property strategy provides protection into 2041 in the US and into 2039 internationally.

Vidofludimus calcium is a small molecule investigational drug in development as an oral treatment option for patients with multiple sclerosis and other chronic inflammatory and autoimmune diseases.

Price: 1.37, Change: -0.01, Percent Change: -0.73